oseltamivir (tamiflu) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Oseltamivir phosphate is an ethyl ester prodrug requiring ester hydrolysis for conversion to the active form, oseltamivir carboxylate. Oseltamivir carboxylate is an inhibitor of influenza virus neuraminidase affecting release of viral particles. Oseltamivir is a well tolerated orally active neuraminidase inhibitor which significantly reduces the duration of symptomatic illness and hastens the return to normal levels of activity when initiated promptly in patients with naturally acquired influenza.   NCATS

Chemistry

  • SMILES: CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1
  • InChIKey: VSZGPKBBMSAYNT-RRFJBIMHSA-N
  • Mol. Mass: 312.41
  • ALogP: 1.29
  • ChEMBL Molecules:
    oseltamivir  
    oseltamivir phosphate  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$0.4165 - $149.5900
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-cyclohexene-1-carboxylic acid, 4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3r-(3alpha,4beta,5alpha))- | ebilfumin | ethyl (3r,4r,5s)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate | oseltamivir | (−)-oseltamivir | oséltamivir | oseltamivir carboxylate | oseltamivir phosphate | oseltamivirum | ro-640796 | ro-640796002 | ro-64-0796-002 | tamiflu | tamvir

Organizations (157)

Research & Development (135)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (23)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (28)

Approved Indications (2)


 

Influenza, Human

Kidney Failure, Chronic

Experimental Indications - Clinical Trial Phases 1-4 (28)


 

Atrial Fibrillation (Phase 4)

Atrial Flutter (Phase 4)

Coronavirus Infections (Phase 4)

COVID-19 (Phase 3)

Critical Illness (Phase 2)

Drug Interactions (Phase 1)

Drug Therapy, Combination (Phase 4)

Healthy Volunteers (Phase 2)

Infections (Phase 1)

Influenza A virus (Phase 3)

Influenza, Human ()

Influenza in Birds (Phase 2)

Kidney Failure, Chronic (Phase 1)

Lung Diseases (Phase 1)

Lymphoma (Phase 2)

Metabolic Diseases (Phase 4)

Obesity (Phase 1/Phase 2)

Pneumonia (Phase 4)

Pregnancy (Phase 1)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Purpura, Thrombocytopenic, Idiopathic (Phase 3)

Respiratory Tract Infections (Phase 4)

SARS-CoV-2 (Phase 4)

ST Elevation Myocardial Infarction (Phase 4)

Therapeutic Equivalency (Phase 1)

Thrombocytopenia (Phase 2)

Virus Diseases (Phase 2)

Virus Shedding (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 131
  • # of Trial Organizations: 135

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue